<DOC>
	<DOCNO>NCT01553123</DOCNO>
	<brief_summary>The purpose study determine whether ulipristal acetate effective treatment female anemia associate uterine leiomyoma . The safety product also evaluate .</brief_summary>
	<brief_title>Efficacy Safety Study Ulipristal Acetate Females With Anemia Associated With Uterine Leiomyoma</brief_title>
	<detailed_description>This randomize , placebo control , multicenter study parallel group order evaluate efficacy safety ulipristal acetate female subject anemia associate uterine leiomyoma . The objective study determine daily ulipristal acetate iron effective iron alone .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Is premenopausal female , 18 50 year ; Has document leiomyoma ( ) ; Has leiomyomarelated anemia ; Has endometrial biopsy within screen period prior first dose test article show endometrial hyperplasia ; Is willing able provide write informed consent authorization disclose protected health information . Has history uterine surgery would interfere study ; Has condition require immediate intermittent blood transfusion ; Has know coagulation disorder ; Has history uterine , cervix , ovarian , breast cancer ; Has use selective progesterone receptor modulator gonadotrophin release hormone agonist previous 6 month ; Has receive blood transfusion within 8 week screen visit ; Has abnormal liver function ; Is pregnant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Leiomyomas</keyword>
</DOC>